[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354182-105":59,"doc-detail-354182-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","phase-ii-randomized-study-of-mk-2206-and-bicalutamide-in-prostate-cancer-patients-with-rising-psa-after-primary-therapy-ecog-acrin-e2809","Phase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809)","","Background: Combined inhibition of AKT and the androgen receptor (AR) may be more effective than AR inhibition alone for biochemical recurrence (BCR) in prostate cancer by additive effects on two effector pathways. Patients and Methods: E2809 enrolled 108 high-risk BCR patients in two phases with 4-week cycles. The PreBic phase (3 cycles) assessed whether AKT inhibition changed PSA, followed by a bicalutamide (Bic) phase in which each arm received Bic with differing AKT exposure. Exploratory endpoints compared PSA response and progression rates. Results: PreBic showed higher PSA rises with MK-2206, while inter-arm responses were similar at EP1, and progression differed at later endpoints. Conclusions: Combined MK-2206+Bic versus Bic alone improved outcomes in a subgroup linked to AR activation crosstalk after AKT inhibition, with toxicity influencing sustained inhibition tolerance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/phase-ii-randomized-study-of-mk-2206-and-bicalutamide-in-prostate-cancer-patients-with-rising-psa-after-primary-therapy-ecog-acrin-e2809/354182/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/phase-ii-randomized-study-of-mk-2206-and-bicalutamide-in-prostate-cancer-patients-with-rising-psa-after-primary-therapy-ecog-acrin-e2809/354182.png","ImageObject",300,407,{"name":92,"@type":93},"Terk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of the ECOG-ACRIN E2809 Phase II trial?","Question",{"text":112,"@type":113},"To test whether combined inhibition of AKT and the androgen receptor provides better control of biochemical recurrence in high-risk prostate cancer compared with androgen-receptor inhibition alone, using PSA-based endpoints across two treatment phases.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients assigned and treated in the trial phases?",{"text":117,"@type":113},"E2809 assigned 108 high-risk BCR patients 1:1 into arm-A and arm-B across two phases with 4-week cycles: a PreBic phase evaluating AKT inhibition effects, followed by a bicalutamide (Bic) phase where Bic was added to each arm with arm differences in prior AKT exposure.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes differed between the combined therapy and Bic alone?",{"text":121,"@type":113},"At an exploratory endpoint (EP2), progressive disease was greater in arm-A than arm-B. Subgroup analyses based on PSA rise during PreBic (PBPD) showed PD at EP2 occurred more often in arm-A than arm-B, supporting a subgroup-driven benefit linked to AR activation crosstalk.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354182,1790177124,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","The Prostate   \nORIGINAL ARTICLE   \nPhase II Randomized Study of MK‐2206 and Bicalutamidein Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG‐ACRIN E2809)  \nAnna C. Ferrari1  | Yu‐Hui Chen2 | Ronald Rodríguez3 | Gary R. Hudes4 | Emmanuel S. Antonarakis5 | Noah M. Hahn5 | Hilary Ma6 | Elizabeth R. Plimack4 | Tina Mayer7 | Bradley C. Carthon8 | Glenn Liu9 | Michael A. Carducci5 | Robert DiPaola10  \n1Montefiore‐Einstein Comprehensive Cancer Center, Bronx, New York, USA | 2Dana Farber Cancer Institute – ECOG‐ACRIN Biostatistics Center, Boston, Massachusetts, USA | 3University of Texas Health Science Center, San Antonio, Texas, USA | 4Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA | 5Johns Hopkins University, Baltimore, Maryland, USA | 6M D Anderson Cancer Center, Houston, Texas, USA | 7Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA | 8Emory University, Atlanta, Georgia, USA | 9University of Wisconsin‐Madison, Madison, Wisconsin,  \nUSA | 10University of Kentucky, Lexington, Kentucky, USA  \nCorrespondence: Anna C. Ferrari ([aferrari@montefiore.org](aferrari@montefiore.org); [anna.ferrarip@outlook.com](anna.ferrarip@outlook.com))  \nReceived: 15 July 2025 | Revised: 16 December 2025 | Accepted: 7 January 2026  \nKeywords: AKT inhibitor | bicalutamide | high‐risk biochemical recurrence | prostate cancer  \nABSTRACT  \nBackground: Combined inhibition of AKT and the androgen receptor (AR) might be more efficacious than AR inhibition alone in biochemical recurrence (BCR) of prostate cancer (PC) by additive effects on the two effector pathways.  \nPatients and Methods: E2809 assigned 108 high‐risk BCR patients (1:1, arm‐A: arm‐B) to two phases with 4‐week cycles: first (PreBic) phase (3 cycles), arm‐B received AKT inhibitor MK‐2206 200 mg 2x/week, arm‐A was observation; second phase, bicalutamide (Bic), 50 mg daily, was added to each arm. The PreBic phase assessed whether AKT inhibition changed PSA, reflecting AR activation. Exploratory primary endpoint (EP1) at 6–8 Bic cycles and secondary EP2 at cycle 14 compared the proportion of cases with ≥stable disease (SD) or progressive disease (PD) .  \nResults: PreBic phase: 70% arm‐B vs 32% arm‐A patients had a ≥ 60% PSA rise (p = 0.02). MK‐2206 skin toxicity (38% grade ≥ 3) drove high withdrawal prior to EP1 . Bic phase: at EP1, inter‐arm PSA response (81%/82%) or PD (19%/18%) was equal. At EP2, PD was greater in arm‐A than arm B (36% vs 11%; p = 0.04). In subgroups defined by PreBic phase PD (PBPD; PSA rise ≥ 25%), 9/16 arm‐A vs 0/7 arm‐B cases experienced PD at EP2 (p = 0.02); overall between PBPD‐subgroups, 73% arm‐A vs 27% arm‐B experienced PD.  \nConclusions: The results suggest that latent improved outcome of high‐risk BCR patients (mean PSA doubling time 4.4 months) on combined MK‐2206+Bic versus Bic alone was attributable to a subgroup identified by crosstalk AR activation secondary to inhibition of AKT. Toxicity may affect tolerance of sustained AKT‐AR inhibition.  \nClinical Trial Registration: ClinicalTrials. gov number, NCT01251861 .  \n1 | Introduction  \nOf men treated with curative intent for localized prostate cancer (PC) by radical prostatectomy (RP) and/or radiation therapy (XRT) with or without androgen deprivation therapy (ADT), 25%–30% will experience biochemical recurrence (BCR)  \nwithout radiographic metastasis [1–3] . BCR is defined by prostate‐specific antigen (PSA) values > 0.2 ng/mL following RP or > 2 ng/mL above the nadir after XRT. It precedes but does not necessarily lead to clinical metastasis within 7–8 years [4–6] . The most reliable measure of PC progression dynamics  \nThis is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2026 The Author(s) . The Prostate published by Wiley Periodicals LLC.  \nThe Prostate, 2026; 8","cbCaiqV5FSfpwpPI","https://ap.wps.com/l/cbCaiqV5FSfpwpPI","pdf",1030344,13,"English","# Introduction\n## Biochemical recurrence definition and risk stratification\n## Androgen receptor signaling and treatment limitations\n# Study design and phases (PreBic and Bic)\n## Endpoints and PSA response assessment\n# Results\n## PreBic phase PSA rise and toxicity impact\n## Bic phase inter-arm response and progression differences\n# Conclusions","[{\"question\":\"What is the main purpose of the ECOG-ACRIN E2809 Phase II trial?\",\"answer\":\"To test whether combined inhibition of AKT and the androgen receptor provides better control of biochemical recurrence in high-risk prostate cancer compared with androgen-receptor inhibition alone, using PSA-based endpoints across two treatment phases.\"},{\"question\":\"How were patients assigned and treated in the trial phases?\",\"answer\":\"E2809 assigned 108 high-risk BCR patients 1:1 into arm-A and arm-B across two phases with 4-week cycles: a PreBic phase evaluating AKT inhibition effects, followed by a bicalutamide (Bic) phase where Bic was added to each arm with arm differences in prior AKT exposure.\"},{\"question\":\"What outcomes differed between the combined therapy and Bic alone?\",\"answer\":\"At an exploratory endpoint (EP2), progressive disease was greater in arm-A than arm-B. Subgroup analyses based on PSA rise during PreBic (PBPD) showed PD at EP2 occurred more often in arm-A than arm-B, supporting a subgroup-driven benefit linked to AR activation crosstalk.\"}]","Phase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809) | PDF",1790109371,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb3570a658b7e41b98c0340d31bf2afc.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0eb9a84d00fb833519c9432050cb467.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e13c4d405a54c4b520f244c6ae23d8a.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f537a51039f6cd2595ce7c7b86f0419.webp",980,1287]